^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

BCL2 (B-cell CLL/lymphoma 2)

i
Other names: BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
1d
PD1-VEN-CAG: PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL (clinicaltrials.gov)
P3, N=40, Active, not recruiting, Fujian Medical University Union Hospital
New P3 trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
Venclexta (venetoclax) • cytarabine • aclarubicin
1d
Diosmetin overcomes resistance to cisplatin in ovarian cancer by suppressing the MAPK signaling pathway. (PubMed, Med Oncol)
Mechanistically, compared with Dio or DDP treatment alone, combined Dio and DDP treatment suppressed the MAPK signaling pathway, represented by reduced phosphorylation of JNK, ERK, and P38. These findings demonstrated that Dio potentiates the anticancer effects of DDP both in vitro and in vivo, indicating that Dio is a promising adjuvant for OC treatment.
Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
|
cisplatin
1d
Osthole attenuates trastuzumab-induced cardiotoxicity in mice by enhancing autophagy via regulating the p38MAPK/mTOR signaling pathway. (PubMed, J Tradit Complement Med)
While these effects were blocked by autophagy inhibitor 3-MA or p38MAPK inhibitor SB203580. These results indicated that OST has a protective effect on TRZ-induced cardiotoxicity, and its underlying mechanism may be related to enhancing autophagy via the p38MAPK/mTOR signaling pathway, thus reducing oxidative stress and apoptosis.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • BECN1 (Beclin 1)
|
Herceptin (trastuzumab)
1d
Effect of Small Nuclear RNA 64 (SNORA64) on Apoptosis Regulator Genes in Pancreatic Cancer in Vitro. (PubMed, F1000Res)
The SNORA64 interactions with apoptotic inhibitor molecules and downregulation of pro-apoptotic molecules significantly sustain cellular viability. Therefore; SNORA64 can be used to increase the cell sensitivity to death during treatment.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • BID (BH3 Interacting Domain Death Agonist) • BAD (BCL2 Associated Agonist Of Cell Death)
1d
Anti-inflammatory effects of 3PO in asthmatic airway inflammation: an integrated study using network pharmacology, molecular modelling, and in vivo experiments. (PubMed, Front Pharmacol)
Furthermore, 3PO treatment reversed key protein changes in lung tissue by increasing inhibitor of nuclear factor Kappa B-α(IKB-α) and decreasing p-NF-κB P65. These results indicate that 3PO exerts anti-inflammatory effects in asthma, and this process is associated with the suppression of the NF-κB pathway, providing a novel therapeutic rationale for asthma therapy.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • CASP3 (Caspase 3) • CCL11 (C-C Motif Chemokine Ligand 11) • IL17A (Interleukin 17A) • IL13 (Interleukin 13) • IL1B (Interleukin 1, beta) • IL4 (Interleukin 4) • IL5 (Interleukin 5) • MAPT (Microtubule Associated Protein Tau) • PFKFB3 (6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 3) • RELA (RELA Proto-Oncogene)
1d
Disrupting the TGF-β-regulated epithelial-mesenchymal transition, apoptotic and autophagic phenotypes of 3D glioblastoma spheroids via glycolytic inhibition. (PubMed, Explor Target Antitumor Ther)
2-Deoxy-D-glucose (2DG), a glycolytic inhibitor, depleted ATP dose-dependently (30-300 μM) and prevented those increases both at the protein and transcriptional levels. This was also observed in 3D spheroids upon TGF-β transient siRNA-mediated silencing or when TGF-βR1 kinase activity was inhibited by galunisertib...3D spheroids require ATP and a TGF-β/TGF-βR1 autocrine signaling axis to recapitulate the apoptosis/autophagy phenotypes. Combining glycolysis inhibition with TGF-β signaling inhibition could offer a promising therapeutic strategy for this rare and lethal brain cancer.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • FASLG (Fas ligand) • TGFB1 (Transforming Growth Factor Beta 1) • CASP7 (Caspase 7) • PIK3C3 (Phosphatidylinositol 3-Kinase Catalytic Subunit Type 3) • ATG16L1 (Autophagy Related 16 Like 1) • ATG7 (Autophagy Related 7)
|
galunisertib (LY2157299)
1d
Loss of Frmd5 Inhibits Jak2-Stat3 Signalling Pathway and Impairs Cell Apoptosis During Vagina Luminal Formation in Puberty Mice. (PubMed, Int J Biol Sci)
A total of 56.7% Cdh16-Cre+; Frmd5flox/flox mice failed to form vaginal lumen and developed longitudinal vaginal septum coupled with infertility in these mice. In summary, we demonstrated that Frmd5 is essential for activation of Jak2-Stat3 signaling pathway and is required for vaginal lumen development in mice.
Preclinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1) • CASP3 (Caspase 3) • CASP8 (Caspase 8)
1d
C/EBP-β Mediates the Reversal of Sorafenib Resistance by Tunicamycin in Hepatocellular Carcinoma. (PubMed, J Hepatocell Carcinoma)
Our study identified C/EBP-β as a key effector of the terminal pro-apoptotic ER stress response. While the direct clinical application of TM is limited by its systemic toxicity, these findings highlight the clinical translational potential of targeting the ER stress-C/EBP-β axis, offering a novel combination therapeutic strategy for patients with acquired sorafenib resistance.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3)
|
sorafenib
1d
An In-Vitro Laboratory Exploration Revealed the Antitumor Effects of Melittin on Osteosarcoma CVCells. (PubMed, Curr Med Chem)
The research demonstrated the anti-OS effects of melittin and its possible relationship with the PI3K/AKT/mTOR pathway.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3)
1d
Jingfang granules alleviate atopic dermatitis by restoring skin barrier function and inhibiting NF-κB/NLRP3 axis and JAK/STAT3 axis. (PubMed, Phytomedicine)
The present study confirmed that JFG alleviate atopic dermatitis by restoring skin barrier function and inhibiting NF-κB/NLRP3 axis and JAK/STAT3 axis. JFGs demonstrate potential therapeutic efficacy for treating AD.
Journal • IO biomarker
|
EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CLDN1 (Claudin 1) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • NLRP3 (NLR Family Pyrin Domain Containing 3) • TJP1 (Tight Junction Protein 1) • OCLN (Occludin)
2d
New P2 trial
|
TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
TP53 mutation
|
cytarabine • Yescarta (axicabtagene ciloleucel) • carmustine • melphalan
2d
New P2 trial
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Epidaza (chidamide) • Hetronifly (serplulimab)